[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354973-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354973-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plk1-stabilizes-catenin-to-drive-colorectal-carcinogenesis-through-nfkb2-mediated-transcriptional-activation-of-usp2a-and-site-specific-phosphorylation","PLK1 stabilizes β-catenin to drive colorectal carcinogenesis through NFKB2-mediated transcriptional activation of USP2a and site-specific phosphorylation","","The study investigates how the Wnt/β-catenin pathway drives colorectal cancer and why direct targeting is hindered by toxicity and adaptive resistance. Polo-like kinase 1 (PLK1) is examined as an upstream regulator, focusing on β-catenin ubiquitination control. RNA-seq co-expression and mechanistic experiments identify PLK1-mediated phosphorylation and NFKB2-driven transcriptional upregulation of USP2a, enhancing β-catenin nuclear accumulation. PLK1 inhibition destabilizes β-catenin and suppresses CRC growth, with rescue assays defining a mechanistic hierarchy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plk1-stabilizes-catenin-to-drive-colorectal-carcinogenesis-through-nfkb2-mediated-transcriptional-activation-of-usp2a-and-site-specific-phosphorylation/354973/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plk1-stabilizes-catenin-to-drive-colorectal-carcinogenesis-through-nfkb2-mediated-transcriptional-activation-of-usp2a-and-site-specific-phosphorylation/354973.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is targeting Wnt/β-catenin signaling difficult in colorectal cancer?","Question",{"text":63,"@type":64},"Therapeutic targeting is limited by on-target toxicity to normal cells and adaptive resistance mechanisms that reduce clinical efficacy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What mechanism does PLK1 use to stabilize β-catenin in CRC?",{"text":68,"@type":64},"PLK1 directly phosphorylates β-catenin at Ser311 to promote USP2a recruitment and protect it from proteasomal degradation, and it also activates NFKB2 to transcriptionally upregulate USP2a.",{"name":70,"@type":61,"acceptedAnswer":71},"How do the results support the therapeutic potential of inhibiting PLK1?",{"text":72,"@type":64},"Genetic or pharmacological inhibition of PLK1 destabilizes β-catenin and reduces CRC proliferation in vitro and in vivo, and the PLK1–NFKB2–USP2a–β-catenin axis suggests a rationale for disrupting Wnt-driven tumorigenesis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354973,1790191008,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Theranostics 2026, Vol. 16, Issue 7 3488  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2026; 16(7): 3488-3506. doi: 10.7150/thno.122368  \nResearch Paper  \nPLK1 stabilizes β-catenin to drive colorectal carcinogenesis through NFKB2-mediated transcriptional activation of USP2a and site-specific phosphorylation  \nYan Li, Lili Zhao, Jiaqiang Deng, Songmei Lu, Jingyu Du, Chen Chen, Li Zhao, Zhiyun Xu, Wencan Wang, Yundi Wang, Fangdong Zou􀀍  \nCollege of Life Sciences, Key Laboratory of Bio-Resources and Eco-Environment of Ministry of Education, Sichuan University, Chengdu, 610065, China.  \n􀀍 Corresponding author: [fundzou@scu.edu.cn](fundzou@scu.edu.cn).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.07.24; Accepted: 2025.12.15; Published: 2026.01.01  \nAbstract  \nRationale: The Wnt/β-catenin signaling pathway is crucial in driving colorectal cancer (CRC), but therapeutic targeting is difficult due to on-target toxicity and adaptive resistance. Polo-like kinase 1 (PLK1), an essential regulator of mitosis, is known to stabilize β-catenin in various cancers. However, its specific mechanistic role in CRC, especially regarding the regulation of β-catenin ubiquitination, remains unclear.  \nMethods: We integrated RNA-seq co-expression analysis with functional studies in CRC models, employing coimmunoprecipitation, ubiquitination assays, luciferase reporter systems, site-directed mutagenesis, and in vivo xenograft experiments.  \nResults: We identified a dual-axis mechanism through which PLK1 posttranslationally and transcriptionally controls β-catenin stability. First, PLK1 directly phosphorylates β-catenin at Ser311, which facilitates its recruitment to the deubiquitinating enzyme USP2a, thereby shielding β-catenin from proteasomal degradation. Second, PLK1 activates the transcription factor NFKB2, which in turn transcriptionally upregulates USP2a, amplifying the deubiquitination capacity of cells. This coordinated regulation ensures robust β-catenin nuclear accumulation and activation of downstream targets such as c-Myc and Cyclin D1 . Inhibiting PLK1, either genetically or pharmacologically, leads to β-catenin destabilization and reduces CRC proliferation in vitro and in vivo. Rescue experiments established a mechanistic hierarchy: USP2aoverexpression cannot restore β-catenin stability when Ser311 phosphorylation is abolished, whereas NFKB2 restoration rescues USP2a expression but not the PLK1 activity-dependent β-catenin‒USP2a interaction.  \nConclusion: Our study identified PLK1 as a key regulator of β-catenin signaling flexibility in CRC, coordinating kinase-dependent and transcriptional mechanisms to sustain pathway activation. The discovery of the PLK1-NFKB2-USP2a-β-catenin axis provides a novel therapeutic rationale for targeting PLK1 to selectively disrupt Wnt-driven tumorigenesis, potentially overcoming the toxicity limitations of conventional Wnt inhibitors.  \nKeywords: PLK1; colorectal cancer; β-catenin; USP2a; NFKB2; Wnt signaling  \nIntroduction  \nColorectal cancer (CRC) is a major cause of cancer-related deaths globally, with over 80% of cases involving abnormal activation of the Wnt/β-catenin signaling pathway [1,2] . The Wnt/β-catenin cascade is a highly conserved pathway critical for embryonic  \ndevelopment and tissue homeostasis, mediating fundamental processes such as stem cell self-renewal and epithelial‒mesenchymal transition [3,4,23,24] . Its molecular mechanism involves a well-orchestrated series of events upon Wnt ligand binding to Frizzled  \nreceptors: this interaction inhibits the β-catenin destruction complex, prevents β-catenin phosphorylation and ubiquitination, and promotes its cytoplasmic accumulation and subsequent nuclear t","cbCaimDarZEapuet","https://ap.wps.com/l/cbCaimDarZEapuet","pdf",16386925,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Why is targeting Wnt/β-catenin signaling difficult in colorectal cancer?\",\"answer\":\"Therapeutic targeting is limited by on-target toxicity to normal cells and adaptive resistance mechanisms that reduce clinical efficacy.\"},{\"question\":\"What mechanism does PLK1 use to stabilize β-catenin in CRC?\",\"answer\":\"PLK1 directly phosphorylates β-catenin at Ser311 to promote USP2a recruitment and protect it from proteasomal degradation, and it also activates NFKB2 to transcriptionally upregulate USP2a.\"},{\"question\":\"How do the results support the therapeutic potential of inhibiting PLK1?\",\"answer\":\"Genetic or pharmacological inhibition of PLK1 destabilizes β-catenin and reduces CRC proliferation in vitro and in vivo, and the PLK1–NFKB2–USP2a–β-catenin axis suggests a rationale for disrupting Wnt-driven tumorigenesis.\"}]","PLK1 stabilizes β-catenin to drive colorectal carcinogenesis through NFKB2-mediated transcriptional activation of USP2a and site-specific phosphorylation | PDF",1790115189,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7a64da3dbeb2ada9d9b84d10b47384b.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc8c1ede784ba912c4d06dab304a4f64.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20c5da0675e32a663bef3e6730dbd41c.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60cbcbc481728c7ed86423d2dd3f8bed.webp",980,1268]